Nominations for the 2014 award are now closed.
The Award and Lecture
The AACR and the Rosenthal Family Foundation established this award in 1977 to recognize research that has made, or promises to soon make, a notable contribution to improved clinical care in the field of cancer. In its desire to honor and provide incentive to investigators relatively early in their careers, the foundation has stipulated that recipients not be more than 50 years of age at the time the award is received.
The recipient of the 38th Annual AACR Richard and Hinda Rosenthal Memorial Award will receive an honorarium of $10,000, give a 50-minute lecture during the AACR Annual Meeting 2014 in San Diego, CA, USA (April 5-9, 2014), and be given support for the winner and a guest to attend the Annual Meeting.
- Candidacy is open to cancer researchers who are affiliated with any institution involved in cancer research, cancer medicine or cancer-related biomedical science. Such institutions include those in academia, industry or government.
- The award will be presented to an individual investigator.
- Institutions or organizations are not eligible for the award.
- Candidates must not be more than 50 years of age at the time the award is received. For the 2014 award, a candidate's date of birth must be on or after April 10, 1963.
- Candidates must be engaged in the practice of medicine.
Nomination Procedure and Instructions
Nominations are closed.
Nominations may be made by any scientist, whether an AACR member or nonmember, who is now or has been affiliated with any institution involved in cancer research, cancer medicine or cancer-related biomedical science. Candidates may not nominate themselves.
Nominations must be submitted online at https://proposalcentral.altum.com by 4:00 p.m. United States Eastern Time on Thursday, October 24, 2013. Paper nominations will not be accepted.
Nomination materials to be submitted are:
1) Nomination Letter Must:
- be addressed to the Selection Committee; be written in English; and not exceed 1,000 words;
- specify the AACR Award for which the candidate is being nominated;
- contain a concise description of the candidate's research that has made, or promises to soon make, a notable contribution to improved clinical care in the field of cancer, with the publications supporting these accomplishments directly referenced within the letter;
- contain a concise description of the impact of these accomplishments on the field; and
- be signed by the nominator(s).
2) Candidate's CV. The candidate's curriculum vitae in English, including a complete list of the candidate's publications.
3) Summary Statement. A statement, no more than 50 words, summarizing the candidate's research accomplishments for which he or she is being nominated.
Full nomination instructions and program guidelines are available throught the link below and on the proposalCENTRAL website.
Candidates will be considered by a committee of international cancer leaders appointed by the president of the AACR. After careful deliberations by the Award Committee, its recommendations will be forwarded to the Executive Committee of the AACR for final consideration and decision. Selection of the award winner will be made on the basis of the candidate's contribution to improved clinical care in the field of cancer. No regard will be given to race, gender, nationality or religious or political views.
Generously supported by the Rosenthal Family Foundation.
Linda Stokes, Program Associate
American Association for Cancer Research
17th Floor, 615 Chestnut Street
Philadelphia, PA 19106-4404
37th Annual Award Recipient
Fadlo R. Khuri, M.D.
Professor & Chair, Hematology/Oncology
Deputy Director, Winship Cancer Instiute
Emory University School of Medicine
Dr. Khuri delivered his award lecture titled Targeting Survival Signaling in Aerodigestive Cancers
, at the AACR Annual Meeting 2013 in Washington, D.C. The award ceremony and lecture was held on Wednesday, April 10, 2013. Visit the AACR Annual Meeting 2013
page for more information on the Annual Meeting.
Dr. Fadlo R. Khuri is honored for his accomplishments as an investigator in lung and aerodigestive medical oncology.
One of Dr. Khuri’s early accomplishments is the recognition of the potential of oncolytic viral therapy in cancer treatment. ONYX-015 is an adenovirus that selectively replicates in p53-deficient cancer cells and is therefore capable of selectively destructing those cancer cells. Khuri recognized the limitation of standard chemotherapy in cancers with a mutated tumor suppressor p53, and combined ONYX-015 with chemotherapy in a controlled clinical trial. This demonstrated superior disease control in patients with recurrent head and neck cancer, a disease that recurs rapidly with either therapy alone. ONYX-015 was the first viral anticancer agent approved in Asia.
He susequently demonstrated that the expression of retinoic acid receptor and COX-2 indicate poor prognosis in lung cancer, and identified prognostic factors such as DAPK methylation and lack of IL-10 expression that independently predict cancer-specific survival. These studies have added further knowledge to individualized adjuvant therapy. He also showed that farnesyl transferase inhibitors can reverse the resistance of non-small cell lung cancers to taxanes.
Dr. Khuri’s studies toward development of novel cancer agents led to the hypothesis of pharmacologically-enhanced oncogene addiction, which describes the use of anti-cancer agents to enhance the dependency of cancer cells to certain pathways so that the addiction can be exploited for effective treatment strategies. Based on this phenomenon, Khuri, Sun and colleagues discovered that despite mTOR suppression, rapamycin induces the paradoxical up-regulation of Akt. These studies may lead to the development of new oncogenic pathway-targeting agents for cancer treatment. These and other contributions of Dr. Khuri toward testing of novel treatment strategies in clinical trials led to his recognition internationally, in the field of chemoprevention and chemotherapy.
He was instrumental in obtaining the National Cancer Institute (NCI) designation to Winship Cancer Institute in 2009. Additionally, he worked to increase NCI peer-reviewed funding in cancer at Emory, from $7.4 million in 2000 to more than $30 million in 2011. His contribution to cancer research and patient care extend beyond the laboratory. He led the increase in patient enrollment in therapeutic clinical trials from 143 in 2001 to more than 500 in each of the last three years.
Khuri currently serves on the editorial board of AACR’s journal, Cancer Prevention Research, and is the editor-in-chief of American Cancer Society’s Cancer. He is an elected member of the American Society of Clinical Investigation. Additionally, he has received the American Cancer Society Clinical Oncology Career Development Award, the Georgia Cancer Coalition Distinguished Clinical Scholar Award, and the Middle East Medical Assembly’s Naji Sahyoun Memorial Award.
Khuri received his medical degree from Columbia University College of Physicians and Surgeons in New York, N.Y. in 1989. He completed his internship and residency at the Boston City Hospital, Boston University School of Medicine in Massachusetts in 1990 and 1992, respectively, and a fellowship at the New England Medical Center at Tufts University School of Medicine in Boston in 1995.